Dr. Susan O'Brien Compares Ibrutinib With Chemoimmunotherapy in Frontline CLL

Video

In Partnership With:

Susan M. O'Brien, MD, associate director for Clinical Science for the Chao Family Comprehensive Cancer Center, medical director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses how ibrutinib (Imbruvica) compares with chemoimmunotherapy as a frontline treatment for patients with chronic lymphocytic leukemia.

Susan M. O'Brien, MD, associate director for Clinical Science for the Chao Family Comprehensive Cancer Center, medical director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses how ibrutinib (Imbruvica) compares with chemoimmunotherapy as a frontline treatment for patients with chronic lymphocytic leukemia (CLL).

Chemoimmunotherapy, comprised of fludarabine, cyclophosphamide, and rituximab (FCR) is a very effective regimen. However, it is not appropriate for elderly patients who are more likely to benefit from a regimen of chlorambucil plus an anti-CD20 agent, O'Brien explains. The rates of progression-free survival are higher in patients who receive ibrutinib versus those who receive chlorambucil plus obinutuzumab, she adds.

For high-risk patients who relapse on FCR or elderly patients, ibrutinib is a more effective choice in the frontline setting, O'Brien explains.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD